Labcorp Launches pTau217 Blood Biomarker Test to Accelerate Path to Diagnosis of Alzheimer's Disease and Support Clinical Trials

Addition of pTau217 test further expands the company's leadership in testing options for Alzheimer's disease to improve patient care  BURLINGTON, N.C. , March 20, 2024 /PRNewswire/ -- Labcorp  (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the

Stage 4 at 34: A woman’s journey from early-onset colon cancer to patient advocacy

After facing early-onset colon cancer, Bridgette is sharing her story of her first colon cancer symptoms and raising awareness of early colon cancer screening.

Labcorp Presents New Research Demonstrating Clinical Impact of Precision Diagnostics in Guiding Biomarker-targeted Therapies for Patients with Epithelial Ovarian Cancer

Outcomes point to value of biomarker testing in addressing testing gaps in clinical practice BURLINGTON, N.C. , March 16, 2024 /PRNewswire/ -- Labcorp  (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today presented the results from two studies at the 2024 SGO

Three ways to be healthy for National Nutrition Month

March is National Nutrition Month® and the theme for this year is “Beyond the Table.” That theme makes us recall the phrase “thinking outside of the box.” So what does that mean? Thinking outside of the box implies breaking free of physical or invisible constraints, traditions and rules. It’s about embracing innovative, creative ideas and using your imagination to explore new ways of doing things instead of doing what’s expected or what’s been done in the past. 

Labcorp Launches Weight Loss Management Testing Solutions

New offering to support individuals and physicians with accessible and convenient testing options to guide weight loss management decisions and treatments BURLINGTON, N.C. , March 7, 2024 /PRNewswire/ --  Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services,

Addressing Challenges with Ulcerative Colitis Clinical Study Recruitment

We understand the significant challenges sponsors face with patient recruitment in their ulcerative colitis (UC) clinical studies. While the prevalence of UC is relatively high (~0.2% in North America, Oceania and much of Europe – and rising in urbanized/industrialized countries in Africa, Asia and Latin America1), recruitment rates into clinical studies are woefully low. Achieving a linear average recruitment rate of just 0.1 patients/site/month* is considered the standard (*calculated by dividing total patient accrual by number of sites by overall recruitment window [months]).